NCT06341296View on ClinicalTrials.gov

Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

December 31, 2026

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Irinotecan Liposome

70 mg/m\^2 , d1, 14 days per cycle, 8 cycles.

DRUG

5-FU

5-FU 400mg/m\^2, then 2400mg/m\^2, continuous intravenous infusion for 46-48h, d1-2, 14 days per cycle, 8 cycles.

DRUG

LV

400mg/m\^2, d1, 14 days per cycle, 8 cycles.

DRUG

Bevacizumab

5mg/kg, d1, 14 days per cycle, 8 cycles.

Trial Locations (1)

610000

RECRUITING

West China Hospital，Sichuan University, Sichuan

All Listed Sponsors
lead

West China Hospital

OTHER